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The costs of accessible quality assured syphilis diagnostics: informing quality 
systems for rapid syphilis tests in a Tanzanian setting  
 
Objectives: To determine the costs of RSTs as compared to RPR when implemented in a Tanzanian 
setting, and to determine the relative impact of a quality assurance (QA) system on the cost of RST 
implementation.  
Methods: The incremental costs for RPR and RST screening programs in existing antenatal care settings 
in Geita District, Tanzania were collected for nine months in subsequent years from nine health facilities 
that varied in size, remoteness, and scope of antenatal services. The costs per woman tested and treated 
were estimated for each facility. A sensitivity analysis was constructed to determine the impact of 
parameter and model uncertainty.  
Findings: In surveyed facilities a total of 6,362 women were tested with RSTs compared with 224 tested 
with RPR. The range of unit costs was $1.76 - $3.13 per woman screened and $12.88 - $32.67 per woman 
treated. Unit costs for the QA system came to $0.51 per woman tested, of which 50% were attributed to 
salaries and transport for project personnel.  
Conclusions: Our results suggest that rapid syphilis diagnostics are very inexpensive in this setting and 
can overcome some critical barriers to ensuring universal access to syphilis testing and treatment. The 
additional costs for implementation of a quality system were found to be relatively small, and could be 
reduced through alterations to the program design. Given the potential for a quality system to improve 
quality of diagnosis and care, we recommend that QA activities be incorporated into RST roll-out. 
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Introduction 
The burden of curable sexually transmitted diseases remains high in many low-income countries. 
According to a WHO estimate, 12 million people are infected with syphilis each year, and 90% of 
infections take place in low-income countries[1]. Syphilis in pregnancy is a leading cause of adverse birth 
outcomes, and is believed to contribute to 650,000 fetal and neonatal deaths each year in developing 
countries[2].  These adverse birth outcomes can be easily prevented with treatment, however symptoms of 
primary syphilis are often unnoticed in women and later stages are often asymptomatic.  Routine 
screening for syphilis during pregnancy has been found to reduce adverse birth outcomes [3] and is 
therefore policy in most sub-Saharan African countries [4-7].   
Adverse outcomes attributable to maternal syphilis infection can be prevented with a single dose of 
benzathine penicillin[8]. As symptoms of primary syphilis are often unnoticed in women and later stages 
are often asymptomatic, universal screening for syphilis infection during pregnancy is the preferred 
intervention for control of congenital syphilis and is policy in most sub-Saharan African countries[9-12].  
The traditional lab-based diagnostic for detection of syphilis, the Rapid Plasma Reagin (RPR) test, is 
often not implemented in low-resource settings due to a number of implementation barriers such as 
electricity, equipment and training; according to Gloyd, et al. (2001) only 38% of all pregnant women are 
screened for syphilis in sub-Saharan Africa[13 14]. The RPR test cannot be performed on whole blood, 
and requires a refrigerator for the reagents and a rotator for test processing[9-12]. Furthermore, even 
where screening is available, diagnostics such as RPR are commonly operated by users without lab 
training and in the absence of a quality system or supportive supervision. While RPR has good sensitivity 
and specificity when performed in a lab setting, ranging from 86-100% and 93-98% respectively, 
environmental and infrastructural factors can compromise the validity of the tests or lead to variability in 
test results.  
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Rapid diagnostics could drastically improve access to and quality of syphilis screening programs in low-
resource settings [13 14].  Unlike RPR, RSTs can be stored at room temperature, performed using whole 
blood, give results within 30 minutes, and do not require additional laboratory infrastructure[15]. 
Diagnostic accuracy of RSTs vary by type; sensitivity and specificity of the SD Bioline using whole 
blood in clinic was found to range from 85.2-100% and 98.1-99.4% respectively2.  
As with many other diagnostics, however, RST validity and accuracy can be compromised due to 
exposure to high temperatures or humidity, manufacturing issues, or operator errors. In order to ensure 
accuracy of diagnosis and quality of care, implementation of a quality assurance (QA) system alongside 
rapid diagnostics is widely advocated [16-19]. A QA system will often be made up of several 
components, including: an in-built control in the test device to verify the specimen was adequate (Internal 
Quality Control); an incoming inspection of test kits to ensure their accuracy has not been compromised 
during transport; regular testing with known positive and negative samples to evaluate accuracy of the test 
kits (External Quality Control); and regular proficiency testing of the operator with blinded positive and 
negative samples (External Quality Assessment). In addition, adequate training and re-training, 
monitoring and supervision are essential to ensure the quality of diagnostic testing. Each component of a 
QA system can be implemented at differing frequencies and intensities, in order to match the specific 
need of the health system in question; the ideal mix of QA components will vary by setting. 
The costs of monitoring and supervision, training, and QA as part of rapid diagnostic test implementation 
are often overlooked[19]. There is very little information on the costs of a QA system as implemented 
alongside rapid tests. The objective of this study is to estimate and compare the costs of RSTs to RPR in 
this Tanzanian setting, and to determine the relative impact of a QA system on the cost of RST 
implementation.  
Methods 
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The Intervention 
Prior to the introduction of RSTs, RPR tests were routinely conducted within MCH units by staff nurses, 
with no regular training or quality assurance in place. The typical RPR testing process in Tanzania is 
described in further detail by Terris Pretholt, et al[20]. 
In September 2009, a pilot program for RST implementation was established by the National Institute for 
Medical Research (NIMR) in Geita District. All health workers conducting screening were given 
intensive training at the start of the project, and routine monitoring and supervision were conducted by 
NIMR staff to assess compliance and ensure quality of diagnosis and patient care. In addition, a robust 
QA system was introduced in February 2010 to ensure diagnostic accuracy. The QA system included each 
of the components described above. External Quality Control was conducted with known positive and 
negative serum samples, which were prepared from whole blood at the NIMR lab in Mwanza and 
delivered to health facilities on a monthly basis. External Quality Assurance was conducted with Dried 
Tube Specimens – a relatively new approach to quality control specimens which does not require cold-
chain support and can be easily produced from whole blood[21]. These were also produced at the NIMR 
lab, and delivered alongside serum samples. 
Cost Analysis 
We collected cost and output data from 9 health facilities which varied in size, remoteness, and scope of 
The incremental costs for RPR and RST screening programs in existing antenatal services provided, 
including three dispensaries (D), five health centers (HC), and one district hospital (DH). Incremental 
financial and economic costs were collected retrospectively from a provider’s perspective, for a nine-
month period in 2009-10 for RSTs. RPR costs were retrospectively collected for a nine-month period in 
2007-08 from six of the nine facilities; three facilities were excluded from the RPR analysis due to 
unavailability of output data (D2, HC5 and DH). Cost data was collected using a combination of standard 
step-down accounting and micro-costing methods[20 22-24]. Costs were collected in Tanzanian shillings 
(TZS) and converted to United States Dollars (USD) using the average exchange rate for 2010 (TZS 
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1,569.04 = 1 USD)[25], then adjusted to 2012 USD using inflation rates from the Consumer Price 
Index[26]. All costs are presented in 2012 USD.  
Cost components include capital and recurrent costs for testing and treatment at the health facility level, 
as well as startup, capital and recurrent costs for RST implementation and quality assurance.  In line with 
the existing literature on syphilis screening in antenatal care, our approach in cost analysis was 
incremental to existing antenatal care services. We only considered new inputs required to add syphilis 
screening to existing ANC services; general administrative or overhead costs required to run the health 
facilities were not included [20]. Where syphilis screening was conducted alongside HIV screening, costs 
such as personnel time and building space were considered to be ‘shared costs’ and divided equally 
between HIV and syphilis screening [20]  
Project outputs and unit costs 
Project outputs were collected retrospectively from patient registers for RST and RPR over the same 
periods as the costs. Intermediate outputs include number of: pregnant women tested, reactive tests, and 
women treated. Unit economic costs per woman tested, and per woman treated were calculated for each 
facility, and for all facilities combined.  
Sensitivity Analysis 
A univariate sensitivity analysis was constructed to determine the impact of uncertainty in cost and output 
collection. We analyzed factors in the sensitivity analysis which could not be directly observed, or which 
varied significantly amongst facilities, including: clinic opening hours, supply wastage, staff time taken 
for testing, staff salaries, and building costs, discount rate, and life of the project. In addition, we 
conducted a multivariate analysis of cost and output factors, simultaneously varying all factors above with 
uniform distribution between the minimum and maximum values observed, over 1,000 iterations.  
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Results 
Project Outputs 
Over a period of nine months in 2009-10, a total of 9,372 pregnant women were tested with RSTs in the 
nine surveyed facilities, covering 87% of women attending antenatal care. Nine hundred twelve (10%) 
tested positive, of which 92% (841 women) were treated. At some facilities, more women were screened 
than were enrolled in ANC – these women were either residents outside the ANC catchment area and not 
captured by the recording system or had been previously enrolled in ANC but not tested until the 
introduction of RSTs.  
 
[table 1 here] 
 
Over a similar time period in 2007-08, a total of 838 women were screened with RPR in six facilities. 
Disaggregated ANC attendance rates during this period were not available, however we found that testing 
rates overall for Geita District during this time were 17.8% [27]. Assuming that ANC attendance rates 
remained relatively constant from 2007/8 to 2009/10 for the facilities included in this analysis, this would 
represent about 12% of women attending ANC at these facilities. Outcome data were unavailable from 
two facilities, and one facility conducted no testing during this period; these three facilities were therefore 
dropped from RPR cost analysis. Two hundred and thirty women (27%) were recorded as reactive, 
although reactivity rates varied from 9%-59% of all women presenting for screening (Table 1). As there 
was no re-testing of samples with a gold standard, the true prevalence of syphilis in these facilities is 
unknown, however a study conducted in 2001 found an average of 8% RPR reactivity in the area[28]. 
This suggests that some facilities had high false-positive rates. Treatment rates for RPR also varied 
widely (11%-90%) but overall only 66% of those testing positive were treated.  
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Costs  
Total economic costs incurred at the health facility level for screening and treatment using RSTs over a 
nine-month period ranged from $751.43 to $5,862.71. RST costs at the health facility level were driven 
by the high unit costs of rapid syphilis tests ($1.10 per test kit); test kits accounted for 41-73% of total 
health facility costs. Personnel time accounted for 11-32% of costs.  
Total costs for the QA system ranged from $513.37 to $554.74 by health facility over the 9-month costing 
period. Costs varied due to differences in transportation costs associated with reaching more remote 
clinics and differences in staff salaries. An incoming inspection of test kits cost $36.46 at the district level 
for each shipment of kits, or an average of $0.70 per health facility. One External Quality Control panel 
cost an average of $22.72 per health facility, while one External Quality Assessment panel cost an 
average of $33.11 per health facility. Salaries and transport for NIMR personnel accounted for 61% of 
costs for External Quality Control, and 50% of costs for External Quality Assessment. One monitoring 
and supervision visit from NIMR personnel cost an average of $23.49 per health facility. Finally, start-up 
and training costs ranged from $184 - $401 by facility, dependent on the number of nurses trained. 
Inclusion of start-up and training, monitoring and supervision, and QA costs increased total costs for RST 
screening to $1,540-$6,777.  
Total economic costs for screening and treatment using RPR ranged from $203.21 to $506.86. Personnel 
accounted for 23%-34% of costs, while supplies accounted for 35%-47%. A significant proportion of 
costs were incurred due to refrigeration of the reagent for RPR; combined equipment and operation 
/maintenance costs represented 13%-34% of costs.  
[table 2] 
Costs were not collected for start-up/training or QA as these activities did not occur under observation 
period of the RPR costing. Costs incurred in district supervision were excluded from both RST and RPR 
cost analysis due to unreliability of reported supervision rates. The total economic cost of one supervisory 
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visit from District Coordinators was found to be $111.09. As District Coordinators are responsible for 
oversight of ANC, PMTCT, and syphilis screening activities, this cost is shared amongst all activities. 
Unit costs 
Unit costs for RST screening at the health facility level were $1.92 per woman screened and $21.35 per 
woman treated. Costs per woman screened varied from $1.74 at HC4 to $3.13 at D1.  
QA costs varied from $0.15 - $2.25 per woman tested. Inclusion of start-up, training and QA costs 
increased unit costs to $2.67 per woman screened (ranging from $2.03 - $6.42) and $29.70 per woman 
treated ($19.19 - $66.96). Economies of scale were apparent in RST testing; costs per woman screened 
were lower at larger health facilities, reflecting a spreading of fixed costs over more women. As QA is a 
large fixed cost, economies of scale are more evident when QA costs are included.  
For RPR screening, unit costs were $2.17 per woman screened (ranging from $1.70-$2.97), and $12.69 
($5.96 - $74.34) per woman treated. Variations in RPR unit cost did not reflect facility size.  
[Table 3] 
Sensitivity Analysis 
We conducted a univariate sensitivity analysis in order to understand the impact of assumptions made in 
collection of cost data and output measures on unit costs at the health facility level. RST costs were 
sensitive to estimates surrounding staff time and supply wastage, while RPR costs were highly sensitive 
to staff time estimates. Decreasing staff time by 50% reduced the average unit cost per woman tested with 
RPR to 1.93. Increasing the estimated supply wastage by 50% increased the estimated unit cost per 
woman tested with RST to 2.42, higher than the base case scenario for RPR.  
[Table 4] 
A multivariate sensitivity analysis was conducted varying staff time and working hours, supply wastage, 
salaries and discount rate, as well as output factors including testing rates,syphilis prevalence, and 
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treatment rates for positive women and their partners. All factors were varied over a uniform distribution 
between the minimum and maximum values observed. Over 1,000 iterations, unit costs for RST testing 
were lower than those for RPR 83% of the time (Figure 1). Lower cost is largely related to economies of 
scale achieved through higher utilization under RST; further research is needed to determine whether this 
increased access is sustainable over a longer term. 
[Figure 1] 
Discussion 
Cost of Screening 
This analysis found the average unit cost at the health facility level for routine screening with RSTs to be 
$1.92 per woman screened. This was lower than the estimated unit cost for RPR ($2.17 per woman 
screened), although direct comparisons varied by health facility. Our results suggest that rapid syphilis 
diagnostics are very inexpensive in a Tanzanian setting, and less expensive than RPR, even where RPR is 
feasible.    
Previously published costs per woman screened with RSTs vary between $1.25 and $4.87 depending on 
prevalence rates, outcome probabilities used, and costs included in the analysis [29-32]. Our finding that 
RST costs for testing and treatment are lower than those for RPR is unique; previous studies have 
reported RST costs per woman screened to be $0.17 – $1.07 higher than those for RPR. The lower costs 
for RST are largely a reflection of economies of scale in implementation – greater access allows fixed 
costs to be spread over a larger number of women.  This may also reflect higher personnel costs for RPR 
testing in Tanzania than those previously recorded, incurred through manual completion of tasks which 
could be performed by equipment in settings with better laboratory infrastructure.  
The Tanzanian Ministry of Health and Social Welfare has expressed plans to scale up RST 
implementation throughout the country following this demonstration project, and has accordingly 
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changed the national syphilis screening guidelines.  We found the startup and training costs to vary 
between $184 - $401 per facility 
 
Access to Screening  
During the study period, syphilis screening rates for women in antenatal care increased under RST 
implementation. In surveyed facilities, the total number of women screened under RSTs was 88% of total 
ANC attendees, as compared to only 12% of ANC attendees screened with the RPR method.  
The increase in number of women tested may be attributable to increased acceptability of the tests by 
health care workers, additional monitoring by project staff, or a reduction in stock outs of essential 
supplies during the RST period. Because they can be ordered in bulk and stored for long periods of time 
without refrigeration, RSTs may be less susceptible to stock-outs than RPR test supplies. RSTs were 
preferred by both health care workers and ANC clients, and found to motivate staff who were happy to 
provide a diagnostic service and immediate treatment to patients [27].  
This study did not evaluate whether increased access to screening was sustained after the project period 
completed; further research is therefore needed to determine the long-term utilization patterns of RST as 
compared to RPR. 
Access to Treatment 
Treatment of reactive patients also increased under RST implementation. The introduction of RST 
witnessed a 30% increase in the number of reactive cases treated compared to RPR. Due to the rapid 
nature of the tests, RST results are available the same day, reducing loss-to-follow up and increasing 
access to treatment.  
Increased access to prompt treatment has the potential to greatly reduce adverse pregnancy outcomes. A 
single dose of penicillin in pregnancy has been proven to reduce the likelihood of adverse birth outcomes 
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due to syphilis.  A study conducted in 2002 in a neighbouring district in Tanzania found that following 
treatment, there was no increased likelihood of adverse outcomes among women with high-titre active 
syphilis, which was determined thought to be correlated with adverse pregnancy outcomes[28], as 
compared to RPR-negative women. A more recent panel of experts with the WHO / child health 
epidemiology reference group (CHERG) has evaluated the literature on maternal syphilis, and estimated 
that treatment can avert adverse outcomes in 48.7% of all women with untreated syphilis in pregnancy, 
regardless of titre [33].  In this study setting, this would mean that treatment has prevented 111 stillbirths, 
68 miscarriages, 163 cases of congenital syphilis, and 106 neonatal and infant deaths.   
Cost of QA 
The QA costs reported reflect current QA implementation for the quality system alongside RST in 
Tanzania. This includes joint monitoring and supervision / QA visits to all health facilities once per 
month, with External Quality Control and External QA conducted simultaneously. QA costs were not 
observable for RPR testing, and therefore not reported in this study.  However QA would theoretically be 
a necessary component of any syphilis screening program, and a robust QA system supporting screening 
with RPR would likely carry similar costs. 
The costs and effects of QA are variable according to implementation, and a QA program can be designed 
for different settings with different disease prevalence levels and to suit different budgets. In areas of high 
disease prevalence, WHO guidelines recommend that quality controls and monitoring are performed 
weekly or even daily to ensure high accuracy of testing and proficiency of personnel[34]. Increasing the 
frequency of on-site External Quality Control samples to a weekly basis would increase External Quality 
Control costs from $21.79 to $35.52 per month. In areas of low disease prevalence, periodic External 
Quality Assessment at a lower frequency is advisable as part of a continuous proficiency assessment of 
personnel, thereby reducing re-training events and increasing confidence of operators.  Decreasing the 
frequency of External Quality Assessment schemes from monthly to quarterly would reduce costs by a 
third, assuming samples are also manufactured quarterly.  
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Altering the frequency of QA activities will influence the cost of the program, although care should be 
taken to ensure the scheme is sufficient to meet the needs of the system. Reduced intensity of Quality 
Assurance could lead to inaccuracy in testing, especially in areas where there is high turnover of staff.  
This might result in high numbers of false positive or false negative test results.  The importance of QA in 
ensuring the quality and accuracy of testing is further discussed by Mabey, et al[27].   
The number of events necessary to validate the test kits after shipment can be reduced by centralizing the 
supply and inventory system, reducing the number of actors in the distribution channel, and ensuring 
adequate temperature monitoring, although minimum performance requirements should be established to 
avoid unnecessary time-consuming and unproductive testing.  
Decentralization of QA responsibilities to the District level and integration with other projects can also 
influence QA cost. The majority of costs for both External Quality Control and External Quality 
Assessment presented reflect transport and personnel costs associated with bringing NIMR personnel 
from Mwanza for delivery of QA materials, monitoring and supervision. Where District Coordinators are 
already conducting monitoring and supervision for other programs the incremental cost of integrating a 
QA component would be minimal.  
Finally, QA is a fixed cost at clinic level and therefore exhibits economies of scale in implementation. 
Unit costs for QA activities varied from $0.15 per woman tested at the largest health facility (DH) to 
$2.25 per woman tested at the smallest health facility (D1). Given the economic gains from implementing 
QA at larger health facilities, a valid interim solution may be to implement QA at larger health facilities 
first, expanding to smaller health facilities when economically possible.  However it is often the small 
clinics that need it most.    
Limitations 
There are a number of limitations to this study which may affect generalisability of the results. Primarily, 
it is difficult to determine the potential changes in access to and cost of services upon scale-up of rapid 
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testing and transfer of QA responsibility to the MoH.  Although the pilot project was designed to maintain 
minimal impact on the health system, NIMR did provide support that may not be sustainable under the 
MoH. For example, NIMR provided additional support to the supply chain throughout the project, 
decreasing the frequency of supply stock-outs and thereby increasing access to screening and treatment 
for syphilis. It is also possible that frequency and intensity of monitoring/supervision will change 
substantially if decentralized to the district level, possibly impacting the success of the QA system.   
This study also did not confirm diagnoses with a gold standard, making it difficult to estimate health 
outcomes (such as DALYs). The lack of a gold standard also prevented confirmation that the introduction 
of RSTs along with a robust quality system improved the accuracy of diagnosis. We also found some 
gaps in cost data for RPR testing. We used original RPR cost data from a previously published study in 
Geita District [35] where data was lacking, inflated to 2012 USD[26]. Finally, the impact of QA on total 
costs of RST screening per woman is likely underestimated. QA activities were not started in Tanzania 
until February 2010 after the screening program had been running for three months, thus potentially 
underestimating costs by up to a third. Table 3 provides the building blocks to estimate the replication 
costs of QA under different configurations. 
As noted by McIntiyre et al.[36], access to health care or health services is a multidimensional concept 
and not directly measureable from utilization data. Further dimensions of access include hours and 
location of services, expectations and attitudes between providers and patients, and range of services 
provided relative to need. Mabey et al.[27] further discuss acceptability of RSTs amongst clients and 
health care workers in this setting, however this project was not designed to estimate other components of 
health care access.  
Conclusions 
The cost-effectiveness of RSTs has been previously proven. This study reports the relative costs of a 
quality control system, when implemented alongside RST testing in a Tanzanian setting. We find that QA 
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has a small additional cost to rapid syphilis screening, but potentially improves quality of diagnosis 
considerably. QA costs could be further reduced through alterations in the program design, including 
changes in frequency of QA activities, integration with other programs, and decentralization to the district 
level. Rapid syphilis screening services are currently being expanded throughout the country as part of the 
Ministry of Health’s efforts to increase access to syphilis screening in antenatal care. Given the small 
incremental costs and potentially significant improvements in quality of diagnosis, we argue that roll-out 
of RSTs should include a QA and monitoring/supervision system in order to improve the validity and 
quality of diagnosis and treatment.  
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Table 1:  Screening and Treatment Output 
D1 D2 D3 HC1 HC2 HC3 HC4 HC5 DH  TOTAL 
                       
Total ANC Clients 196 594 735 707 792 723 1667 1412 3885  10,711 
              
RPR                    
Total Tested 85 38 81 197 217 110 110 0 N/A  838 
Total Positive 50 14 27 95 21 13 10 0 N/A  230 
Total Treated  23 N/A 3 85 19 8 5 0 N/A  143 
              
% of ANC Tested 43% 6% 10% 28% 27% 15% 7% 0% -  12% 
% Reactive 59% 37% 33% 48% 10% 12% 9% - -  27% 
% of Positive Treated 46% - 11% 89% 90% 62% 50% - -  62% 
             
RST            
Total Tested 240 481 666 809 819 517 1135 1371 3334  9,372 
Total Positive 23 53 105 74 122 58 107 102 268  912 
Total Treated  23 52 88 70 116 51 105 102 234  841 
             
% of ANC Tested 122% 81% 91% 114% 103% 72% 68% 97% 86%  87% 
% Reactive 10% 11% 16% 9% 15% 11% 9% 7% 8%  10% 
% of Positive Treated 100% 98% 84% 95% 95% 88% 98% 100% 87%  92% 
N/A – Data not available 
             
RST outputs: 1st October 2009 through 30th June 2010 
RPR outputs: 1st May 2007 – 31st January 2008
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Table 2: Total Screening Costs 
RPR Costs RST Costs 
D1 D3 HC1 HC2 HC3 HC4 D1 D2 D3 HC1 HC2 HC3 HC4 HC5 DH 
Start-up and Training Costs 
N/C 
249 221 212 187 197 184 298 262 402 
Quality Assurance Costs 539 896 555 844 535 534 533 545 513 
Monitoring and Supervision Visit (x5) 24 23 24 26 23 22 23 25 21 
Incoming Inspection (x4) 1 1 1 1 1 1 1 1 1 
External Quality Control Panel (x5) 23 23 23 24 23 22 23 23 22 
External Quality Assurance Panel (x5) 33 33 33 33 33 33 33 33 32 
Testing and Treatment Costs 
Capital 31 37 48 40 30 30 43 142 22 89 60 48 48 24 194 
Personnel 88 67 182 134 51 101 435 741 570 656 435 361 412 543 1,217 
Supplies 97 77 240 166 85 103 457 868 1,027 1,235 1,188 928 1,705 2,119 4,595 
Other 40 41 43 42 41 40 41 61 56 52 48 44 25 36 66 
Total Testing Costs 256 223 512 382 207 274 1,540 2,399 2,206 2,573 2,242 1,877 2,802 3,301 6,778 
 
N/C: Data not collected 
All values rounded to the nearest dollar
Table 3: Unit Costs per Woman Tested 
 
RPR RST 
Average Min Max Percent  Average Min Max Percent
Startup and Training Costs             
Training 
N/C 
0.18 0.10 0.78 
Other start-up 0.06 0.02 0.26 
Total Startup Costs 0.24 0.12 1.04 
Quality Costs 
Monitoring and Supervision 0.32 0.07 1.27 
Incoming Inspection 0.00 0.00 0.01 
External Quality Control 0.11 0.03 0.48 
External Quality Assurance 0.16 0.05 0.69 
Total Quality Costs 0.59 0.15 2.25 
Testing and Treatment Costs 
Buildings and Storage 0.06 0.03 0.11 3% 0.07 0.02 0.30 4%
Equipment 0.20 0.12 0.43 9% - - - 0%
Personnel 0.74 0.46 1.04 34% 0.33 0.19 1.00 17%
Supplies 0.92 0.76 1.22 41% 1.51 1.38 1.80 78%
Test Kits 0.73 0.64 0.85 33% 1.29 1.29 1.29 67%
Treatment Supplies 0.14 0.03 0.33 6% 0.08 0.05 0.14 4%
Other Supplies 0.05 0.04 0.09 2% 0.14 0.04 0.50 7%
Building Operation and Maintenance 0.29 0.19 0.49 13% 0.00 - 0.03 0%
Waste Management 0.01 0.00 0.01 0% 0.01 0.00 0.05 1%
Total Testing and Treatment Costs 2.21 1.76 3.02 100% 1.92 1.74 3.13 100%
Total Costs 2.21 2.74 
 
N/C: Not collected 
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Table 4: Univariate Sensitivity Analysis 
       Univariate Sensitivity Analysis Results 
(% divergence from base case)        
  Observed Values  RST  RPR 
    
Parameters Varied Minimum Maximum  Minimum Maximum  Minimum Maximum 
Discount rate 1% 6% 1.92 (0%) 1.92 (0%) 2.30 (1%) 2.35 (1%) 
Working hours per day 7 4  1.85  (3%) 2.06  (7%)  2.20  (5%) 2.70  (17%)
Supply wastage 0% 50%  1.80  (6%) 2.42  (26%)  2.23  (4%) 2.67  (15%)
Staff time (+/- 50%) - 50% + 50%  1.77  (8%) 2.07  (8%)  1.93  (17%) 2.71  (17%)
Staff Salaries $139 $624  1.76  (8%) 2.37  (24%)  3.32 (44%) 1.94  (16%)
                
RST Outcomes               
Syphilis Prevalence 7% 16%  
% Positives Treated 84% 100%  
% Partners Treated 14% 100%  
Varied only in  
Multivariate Sensitivity Analysis RPR Outcomes      
% ANC Tested 7% 43%  
Syphilis Prevalence 9% 59%  
% Positives Treated 11% 90%  
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Figure 1: Multivariate Sensitvity Analysis 
